Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Features

1224 Features
The Proper Dose: Interviewing in the Pharmaceutical Industry

17 Aug 11

For recent graduates from science, medicine, or mathematics programs, applying for work in the ever-expanding pharmaceutical industry can be an intelligent choice for both career and financial stability. Depending on the industry upon which you choose to focus, the rules and expectations during the interview process can vary.
Terri Ingot

The Long-term Costs of Health Care

17 Aug 11

Almost irrespective of the country you live in, the increasing costs of healthcare are unavoidable. For governments, the stresses are particularly acute, as both aging populations and the increasing cost of treatments add financial pressures year on year. Yet as a new study by the Institute of Fiscal Studies (IFS) confirms, we should not underestimate the extent to which the shape of the state has already changed.
Max Golby - PharmiWeb Field Reporter

Let the jobs come to you!

04 Aug 11

Find out about the latest jobs that match your search - automatically.
Mike Wood

Vaccines and International Aid

27 Jun 11

At a moment when the national discourse on international aid is grounded in pessimism, David Cameron’s pledge to commit £814m to help vaccinate the world’s poorest children provides an necessary reminder of what international aid really can achieve.
Max Golby

Certolizumab works in RA regardless of prior TNF or concomitant DMARDs

31 May 11

Certolizumab pegol (Cimzia ®) delivered rapid and consistent improvements in a broad range of rheumatoid arthritis (RA) patients after 12 weeks of treatment regardless of whether or not they had received prior TNF inhibitors or whether or not they were receiving concomitant DMARDs, concluded the latest analysis of the Phase III b REALISTIC trial presented at the European League Against Rheumatism (EULAR) meeting in London, May 25-28 (abstract FRI021).
Janet Fricker

FDA set to approve Vertex Pharmaceuticals Inc.'s (VRTX) hepatitis C drug telaprevir and Merck’s hepatitis C drug, broceprevir.

10 May 11

Both drugs are protease inhibitors (PIs) and are designed to block an enzyme that helps the hepatitis C virus replicate. Hepatitis C is a liver disease caused by infection with the hepatitis C virus, which is transmitted through contaminated blood. The infection can cause liver failure and liver cancer.
Rhonda Siddall-Freelance Medical Journalist and Writer

Pharma Marketing: The Power of Taking Your Health Message Mobile

03 May 11

Brand managers and marketing leads are always striving to gain that first step of engagement, particularly in our world of pharmaceutical manufacturing. And with good reason. Customer engagement leads to improved understanding, which drives loyalty and ultimately improved health.
Eric Boothe, Director Business Development—Life Sciences

Candidate Tips – Your eMail Address

03 May 11

In competitive job searching, every little helps, and one thing that is often overlooked is your email address.
Mike Wood

Pharma on Twitter

14 Apr 11

Want to know which Pharma companies are on Twitter? - here's a list..
Mike Wood

The Code: What does it mean for you?

01 Apr 11

This week is Code Awareness Week and the Prescription Medicines Code of Practice Authority (PMCPA) is launching an e-learning module for health professionals
Claire Eldridge, Aurora

Competition in Healthcare

25 Mar 11

Since the very dawn of Western capitalism, competition has been synonymous with success. Indeed, in accounting for the past 500 years of Western ascendancy in the world, Professor Niall Ferguson of Harvard University points to six ‘killer apps’. The first of these, unsurprisingly, is competition
Max Golby

GSK sets new benchmark for graduate recruitment

17 Mar 11

Earlier this month the UK drugs giant GlaxoSmithKline announced a groundbreaking and progressive new scheme for graduates, whereby from 2012 the company will offer to reimburse in full the university tuition fees of the entirety its future graduate intake.
Max Golby

Sanofi-aventis to Acquire Genzyme

24 Feb 11

After six months of sometimes lively pursuit, the French pharmaceutical group, Sanofi-aventis, has agreed a deal to pay $20.1bn in cash for U.S. biotech firm Genzyme Corp after Sanofi made an increased offer of $74 per share.
Max Golby - PharmiWeb Field Reporter

Hold onto Your Top Talent Using Social Media

22 Feb 11

Social networking sites such as Facebook, Linkedin and Twitter are all the rage – there’s no escaping them, they’re everywhere – even in the workplace, and whether you like it or not, they’re not going away.
Catherine Gutsell, CK Group

NextPharma is lowering healthcare costs

18 Feb 11

NextPharma is lowering healthcare costs in an environment of continuing Pharma industry restructuring
NextPharma

9 Point Pre-Interview Checklist

18 Feb 11

If you've got your self an interview for the perfect job - well done! Now comes the hard part, and you only get one chance. So, here's a simple check list of things that should help you keep your cool and allow you to concentrate on sailing through the interview
Mike Wood

How to | Get a job in Pharma using PharmiWeb.com

07 Feb 11

If you are new to using PharmiWeb.com to find a new job, you'll soon realise that we have thousands of jobs listed and that they change every day. This means you may initially find the task a bit daunting. However, it’s not really that hard, and with a bit of thought, you will soon be asking why you didn’t do it years ago.
Mike Wood

The Trouble With Healthcare Reform

19 Jan 11

When David Cameron recently found himself in the hot seat on the BBC’s Andrew Marr Show, one policy area brought challenges beyond all others. Healthcare reform, Mr. Marr suggested in a short exchange, is swiftly becoming a major source of controversy for this government.
Max Golby

Patent Box Confirmed

06 Jan 11

At times of global economic downtown, and internal restructuring within firms, risks to innovation arise. And as businesses look for savings, research and development is seldom exempt.
Max Golby

Pharma Advertising and the EU

02 Dec 10

As a result of a vote taken in the European Parliament earlier this week, patients in the European Union will receive improved information on prescription drugs, in addition to being protected from some of the more potentially exploitable clauses of the Commission’s proposed Directive on Information to Patients.
Max Golby

The NHS in the digital age

25 Nov 10

In an age of competition and choice, patient knowledge is paramount. Between 1997 and 2007, the Blair government’s entire programme of public sector reforms were delivered under the banner of ‘Choice and Competition’.
Max Golby

NGP20 Opens Innovation

22 Nov 10

With the global economy remaining stagnant, big pharma companies are keen to develop blockbuster drugs that have a high financial ceiling. Rodger McMillan, VP of R&D at Astra Zeneca has said that “big pharma is a cash-rich industry – it has to be,” namely because of the huge costs in developing new drugs – sometimes as much as $200 million.
Daniel Reinhold-Shor

The Wired & Unemployed Citizenry

18 Nov 10

In the USA alone, when your neighbor is out of work it is a slowdown, when your family member is added it becomes recession and when you too join the same line than it surely becomes a depression. The unofficial employment in USA being claimed at 15-25 percent while the economical turnaround seems a mirage; the closer you get the clearer becomes the reality, nothing but refractions.
Naseem Javed

Quick Look: NICE

16 Nov 10

In many ways, the National Institute for Health and Clinical Excellence (NICE) embodies many of the characteristics that define the NHS. In a system of universal access — and in a world where resources are finite — tough decisions inevitably have to be made. And by taking difficult decisions, particularly in reference to end of life care, NICE attempts to make the most of the drugs budget we do have.
Max Golby

Epratuzumab a new drug in development for SLE shows promising results in EMBLEM study

12 Nov 10

Epratuzumab, a new humanised IgG1 monoclonal antibody that acts on CD22 (a molecule preventing over-activation of the immune system and emergence of auto-immune diseases) has shown promise as a potential treatment of moderate to severe systemic lupus erythematosus (SLE) according to results of a new study EMBLEM.
Olwen Glynn Owen

Imaging Biomarkers

11 Nov 10

Large pharma has been seeking new biomarkers for years – all part of their drug discovery process, but often only as an afterthought in the development process. That’s changed over recent years, but by-and-large the bulk of biomarker work remains in the hands of small -to -medium-sized companies whose focused approach is more attuned to biomarkers being a major element of a final product.
Daniel Reinhold-Shor

BrightTALK™ Digital Marketing and Pharma Summit

11 Nov 10

As patients and prescribers increasingly move online for their information, how can pharma engage these audiences by incorporating digital marketing into their current plans?
Mike Wood

The Pharma-Nutrition interface: the gap is narrowing

04 Nov 10

Most pharmacologists will acknowledge that nutrition is important for good health and well-being, however, at the same time it is also considered to be a chemical nightmare with unknown effects. This has not always been the case, in the past connections between pharmacology and nutrition has been more intimate, as Hippocrates once stated, ‘‘Let food be thy medicine and let medicine be thy food.
Johan Garssen, PhD, Conference Chairman

The Future of Pharma is Asia

03 Nov 10

Reshaping the pharmaceutical industry's quality standards is currently the top priority for the Chinese government. Earlier announcements by its Ministry of Health to issue new tougher Good Manufacturing Processes (GMP) standards for medical products comes at the right time as current regulations do not meet international standards which result in poor performance by Chinese companies in the international market.
Emma Naylor

Quick Look: Probiotics

27 Oct 10

Now more than ever, alternative science and holistic remedies are playing a role in our lifestyles. But is that right? Over the past year, we've reported on everything from homeopathy to hypnotherapy. Importantly, we've differentiated between those approaches with at least a modicum of evidence to support them, and those without almost any at all. Yet in contrast to homeopathy, perhaps it can be said that our next target has at least a little science to support it.
Max Golby

Advertising